# Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)

Study · id `cardio:ct-nct01414166` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01414166](<https://clinicaltrials.gov/study/NCT01414166>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01414166

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 244 participants.

## Technical summary

Registry record NCT01414166. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-03-14.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 244 participants (enrolled count; ClinicalTrials.gov record NCT01414166, source copy `cardio:ctgov-nct01414166-2015-05-13`, retrieved 2026-10-31)
- Start date: 2011-09 (registry gives no type) (ClinicalTrials.gov record NCT01414166, source copy `cardio:ctgov-nct01414166-2015-05-13`, retrieved 2026-10-31)
- Primary completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01414166, source copy `cardio:ctgov-nct01414166-2015-05-13`, retrieved 2026-10-31)
- Completion: 2013-02 (actual) (ClinicalTrials.gov record NCT01414166, source copy `cardio:ctgov-nct01414166-2015-05-13`, retrieved 2026-10-31)
- Results first posted: 2014-03-14 (ClinicalTrials.gov record NCT01414166, source copy `cardio:ctgov-nct01414166-2015-05-13`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01414166-2015-05-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
- Condition: Dyslipidemia
- Intervention (Drug): ERN/LRPT
- Intervention (Drug): placebo
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: e3b85927bc5cf48e916dc7c07f51e13067c908e37d3e7f0df353da521f42b97e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
